4.7 Article

EZH2 is overexpressed in transitional preplasmablasts and is involved in human plasma cell differentiation

Journal

LEUKEMIA
Volume 33, Issue 8, Pages 2047-2060

Publisher

NATURE PUBLISHING GROUP
DOI: 10.1038/s41375-019-0392-1

Keywords

-

Funding

  1. French INCA (Institut National du Cancer) Institute [PLBIO15-256]
  2. ITMO Cancer (MMTT)
  3. SIRIC Montpellier [INCa-DGOS-Inserm 6045]
  4. Labex EpiGenMed

Ask authors/readers for more resources

Plasma cells (PCs) play a major role in the defense of the host organism against pathogens. We have shown that PC generation can be modeled using multi-step culture systems that reproduce the sequential cell differentiation occurring in vivo. Using this unique model, we investigated the role of EZH2 during PC differentiation (PCD) using H3K27me3 and EZH2 ChIP-binding profiles. We then studied the effect of the inhibition of EZH2 enzymatic activity to understand how EZH2 regulates the key functions involved in PCD. EZH2 expression significantly increases in preplasmablasts with H3K27me3 mediated repression of genes involved in B cell and plasma cell identity. EZH2 was also found to be recruited to H3K27me3-free promoters of transcriptionally active genes known to regulate cell proliferation. Inhibition the catalytic activity of EZH2 resulted in B to PC transcriptional changes associated with PC maturation induction, as well as higher immunoglobulin secretion. Altogether, our data suggest that EZH2 is involved in the maintenance of preplasmablast transitory immature proliferative state that supports their amplification.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Review Cell Biology

Mechanisms of Polycomb group protein function in cancer

Victoria Parreno, Anne-Marie Martinez, Giacomo Cavalli

Summary: Misregulated Polycomb proteins play a pleiotropic role in cancer, altering various biological processes crucial for tumor progression by modulating the expression of key genes in cellular decisions. Interfering with PcG functions can be a powerful strategy to counter tumor progression.

CELL RESEARCH (2022)

Article Biochemistry & Molecular Biology

SETDB1/NSD-dependent H3K9me3/H3K36me3 dual heterochromatin maintains gene expression profiles by bookmarking poised enhancers

Amandine Barral, Gabrielle Pozo, Lucas Ducrot, Giorgio L. Papadopoulos, Sandrine Sauzet, Andrew J. Oldfield, Giacomo Cavalli, Jerome Dejardin

Summary: A study revealed the presence of dual regions with both H3K9me3 and H3K36me3 marks in mouse embryonic stem cells, which lose these marks and gain enhancer signatures upon removal of SETDB1, suggesting an important role for heterochromatin in gene control. In differentiated tissues, some of these dual domains become destabilized and enriched in enhancer marks, providing insight into heterochromatin involvement in cell identity maintenance.

MOLECULAR CELL (2022)

Article Oncology

Targeting the β2-adrenergic receptor increases chemosensitivity in multiple myeloma by induction of apoptosis and modulating cancer cell metabolism

Hatice Satilmis, Emma Verheye, Philip Vlummens, Inge Oudaert, Niels Vandewalle, Rong Fan, Jennifer M. Knight, Nathan De Beule, Gamze Ates, Ann Massie, Jerome Moreaux, Anke Maes, Elke De Bruyne, Karin Vanderkerken, Eline Menu, Erica K. Sloan, Kim De Veirman

Summary: This study investigates the potential therapeutic effects of beta-blockers, specifically targeting the beta(2)-adrenergic receptor, in multiple myeloma treatment. The blockade of beta(2)-adrenergic receptors reduces cell viability, induces apoptosis and autophagy, and modulates cancer cell metabolism. Combining beta(2)AR blockade with other drugs enhances apoptosis in multiple myeloma cells.

JOURNAL OF PATHOLOGY (2023)

Meeting Abstract Hematology

Development of a Robust BH3 Profiling Toolkit for Precision Medicine in Hematologic Malignancies

Valentin Jacquier, Antoine Guillemin, Sara Ovejero-Merino, Guilhem Requirand, Ouissem Karmous-Gadacha, Laure Dutrieux, Andrea Romero, Alizee Steer, Amelie Machura, Hugues De Boussac, Jerome Moreaux, Charles Herbaux

BLOOD (2022)

Article Multidisciplinary Sciences

Topological screen identifies hundreds of Cp190-and CTCF-dependent Drosophila chromatin insulator elements

Tatyana G. Kahn, Mikhail Savitsky, Chikuan Kuong, Caroline Jacquier, Giacomo Cavalli, Jia-Ming Chang, Yuri B. Schwartz

Summary: Drosophila insulators are DNA elements that regulate gene expression by limiting chromatin contacts. By mapping chromatin contacts in Drosophila cells without key insulator proteins CTCF and Cp190, we discovered hundreds of insulator elements. Our findings suggest that Drosophila insulators play a minor role in overall genome folding but have a local impact on chromatin contacts. Our insulator catalog is an important resource for studying genome folding mechanisms.

SCIENCE ADVANCES (2023)

Article Multidisciplinary Sciences

Epigenetic inheritance in adaptive evolution

Gonzalo Sabaris, Maximilian H. H. Fitz-James, Giacomo Cavalli

Summary: Increasing evidence suggests that environmental stress can trigger epigenetic signals that persist over long timeframes, leading to phenotypic changes and potential selection. Epigenetic inheritance plays a crucial role in rapid phenotypic adaptation to fluctuating environments, ensuring short-term survival while maintaining a bet-hedging strategy. These findings call for a reevaluation of the importance of nongenetic information in adaptive evolution and its broader relevance in nature.

ANNALS OF THE NEW YORK ACADEMY OF SCIENCES (2023)

Article Biochemistry & Molecular Biology

3-O sulfation of syndecan-1 mediated by the sulfotransferase HS3ST3a1 enhances myeloma aggressiveness

L. Baert, B. Manfroi, M. Quintero, O. Chavarria, P. V. Barbon, E. Clement, A. Zeller, T. Van Kuppevelt, N. Sturm, J. Moreaux, A. Tveita, B. Bogen, T. McKee, B. Huard

Summary: Multiple myeloma is a hematological neoplasm derived from plasma cells in the bone marrow. A subpopulation of cells called 10e4(+) cells, which have high resistance to multiple myeloma drugs, bind to the protein APRIL through heparan sulfate chains on syndecan-1. These cells have high proliferation activity and are able to form colonies in 3D cultures. They can develop in the bone marrow after intravenous injection and become more resistant to drugs after treatment. The enzyme HS3ST3a1 plays a role in modifying syndecan-1 to confer reactivity to 10e4 and APRIL binding. Targeting this enzyme could potentially improve drug resistance control in multiple myeloma.

MATRIX BIOLOGY (2023)

Article Genetics & Heredity

Var divide Decrypt: a novel and user-friendly tool to explore and prioritize variants in whole-exome sequencing data

Mohammad Salma, Elina Alaterre, Jerome Moreaux, Eric Soler

Summary: Var vertical bar Decrypt is a web-based tool designed to extract relevant functional information from whole-exome sequencing (WES) data. It offers various filtering and analysis tools for prioritizing gene variants. By using Var vertical bar Decrypt, we successfully identified known disease oncogenes and novel putative drivers in WES datasets of acute erythroid leukemia patients.

EPIGENETICS & CHROMATIN (2023)

Article Hematology

Extreme thrombocytosis with an aggressive evolution harboring a novel variant of calreticulin (CALR) in exon 3

Sarah Bonnet, Serge Carillo, Baptiste Legrand, Barbara Burroni, Thierry Lavabre-Bertrand, Guilhem Requirand, Nicolas Robert, Lea Fornero, Ahmed Al Mansoori, Jerome Moreaux, Guillaume Cartron, Ludovic Gabellier, Charles Herbaux

Summary: This case study describes a patient with extreme thrombocytosis who unfortunately had a rapidly fatal outcome. The cause of the thrombocytosis remained unknown and the patient did not show signs of myelofibrosis. However, dysplastic megakaryocytes were observed. The patient had a novel variant of the CALR gene in exon 3 (C105S), as well as mutations in ASXL1, U2AF1, and EZH2. These mutations were found in myeloid cells but not in lymphoid cells. The patient was diagnosed with a rare case of myelodysplastic syndrome/myeloproliferative neoplasm (MDS/MPN). Due to the high risk of thrombosis, the patient was treated with hydroxycarbamide. As the hematological status worsened, two new mutations, SETBP1 and ETV6, appeared, while the CALR mutation and the three other mutations identified in the chronic stage were still detectable. These findings suggest that the CALR variant may contribute to the pathogenesis of MDS/MPN in this patient.

EUROPEAN JOURNAL OF HAEMATOLOGY (2023)

Letter Oncology

EZH2 targeting induces CD38 upregulation and response to anti-CD38 immunotherapies in multiple myeloma

Djamila Chemlal, Emmanuel Varlet, Amelie Machura, Sara Ovejero, Guilhem Requirand, Nicolas Robert, Guillaume Cartron, Elina Alaterre, Caroline Bret, Laure Vincent, Charles Herbaux, Giacomo Cavalli, Angelique Bruyer, Hugues De Boussac, Jerome Moreaux

LEUKEMIA (2023)

Article Medical Laboratory Technology

Immunophenotypic portrait of leukemia-associated-phenotype markers in B acute lymphoblastic leukemia

Emilia Boris, Alexandre Theron, Valentin Montagnon, Nicolas Rouquier, Marion Almeras, Jerome Moreaux, Caroline Bret

Summary: This study aimed to investigate the landscape of 7 leukemia-associated phenotype (LAP) markers in B acute lymphoblastic leukemia (B ALL). The expression levels of these markers in normal leukocytes, normal B cell differentiation, and B lymphoblasts at diagnosis of B ALL were evaluated. The study also examined the prognostic value of these markers using Maxstat R algorithm.

CYTOMETRY PART B-CLINICAL CYTOMETRY (2023)

Meeting Abstract Oncology

Targeting DNMT3B impairs multiple myeloma cell proliferation and clonogenic capacity and enhances sensitivity to standard of care agents

Catharina Muylaert, Lien Ann Van Hemelrijck, Elina Alaterre, Nicolas Robert, Guilhem Requirand, Kim De Veirman, Eline Menu, Karin Vanderkerken, Jerome Moreaux, Elke De Bruyne

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2023)

Meeting Abstract Oncology

Inhibition of proline production by stromal cells negatively impacts myeloma tumor growth by reducing cytokine and growth factor secretion

Inge Oudaert, Judith Lind, Osman Aksoy, Catharina Muylaert, Hatice Satilmis, Sylvia Faict, Jerome Moreaux, Kim De Veirman, Elke De Bruyne, Sonia Vallet, Karin Vanderkerken, Klaus Podar, Eline Menu

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2023)

Meeting Abstract Oncology

Targeting iron homeostasis in combination with IMiDs as a therapeutic strategy in multiple myeloma

Sara Ovejero, Julie Devin, Tatiana Caneque, Laura Henry, Laura Alibert, Guilhem Requirand, Nicolas Robert, Alizee Steer, Amelie Machura, Christophe Hirtz, Angelique Bruyer, Laure Vincent, Guillaume Cartron, Charles Herbaux, Raphael Rodriguez, Caroline Bret, Jerome Moreaux

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2023)

Meeting Abstract Oncology

Exploiting transcription-replication conflicts as a novel therapeutic intervention in multiple myeloma

Laure Dutrieux, Guillemin Antoine, Lin Yea-Lih, Malik Lutzmann, Guilhem Requirand, Nicolas Robert, Laure, Guillaume Cartron, Charles Herbaux, Raphael Rodriguez, Michel Cogne, Philippe Pasero, Jerome Moreaux

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2023)

No Data Available